Is Enbrel a subsidiary?

No. Enbrel is a product brand owned by Amgen Inc., the drug it developed and markets.

Is Enbrel publicly traded?

No. Only the parent, Amgen Inc., is traded, on Nasdaq under ticker AMGN.

When was Enbrel approved?

Immunex received FDA approval for Enbrel in 1998 for rheumatoid arthritis. Amgen acquired it in 2002.

What does Enbrel treat?

Enbrel treats rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, and juvenile idiopathic arthritis.

Enbrel is wholly owned by Amgen Inc., acquired through the 2002 Immunex purchase.

Is Enbrel still a blockbuster?

Enbrel remains a major product generating billions in annual sales, though it has declined from its peak of over $8 billion as newer drugs and biosimilars gained share.

Healthcare & Pharmaceuticals

Who Owns Enbrel?

Enbrel (etanercept) is a biologic medication for rheumatoid arthritis, psoriasis, and other autoimmune conditions, owned by Amgen Inc. (Nasdaq: AMGN). Originally developed by Immunex and acquired by Amgen in 2002, it became one of the highest-selling drugs in pharmaceutical history with peak annual sales exceeding $8 billion.

Parent Company

Amgen Inc.

Acquired

2002

Status

Publicly Traded

Headquarters

Thousand Oaks, California, USA (parent)

Enbrel Timeline

1980

Amgen Inc.

Parent company established in Thousand Oaks, California, USA

Company Founded

1998

Enbrel

Founded by Immunex Corporation (original developer)

Founded

2002

Acquired by Amgen Inc.

Amgen Inc. acquired Enbrel

Acquired

premiummarket leaderGlobalall-agesOfficial Website

Who Owns Enbrel?

Parent Company: Amgen Inc.
Ownership Type: Acquired
Acquisition Year: 2002
Company Type: Publicly Traded
Stock Ticker: NASDAQ: AMGN

Brand	Parent Company	Ownership Type
Enbrel	Amgen Inc.	Acquired

Where to Buy

Disclosure: We may earn commission from purchases

Enbrel on Amazon

History of Enbrel

Founded: 1998
Founders: Immunex Corporation (original developer)
Acquired by Amgen Inc.: 2002

Immunex Corporation developed Enbrel (etanercept), a tumor necrosis factor (TNF) inhibitor, and won FDA approval in 1998 for rheumatoid arthritis, making it one of the first biologic disease-modifying treatments for the condition.

The drug transformed rheumatoid arthritis treatment, shifting patients from symptomatic management toward biologic intervention that could slow disease progression. It became a megablockbuster, eventually reaching peak annual sales exceeding $8 billion, among the highest for any drug in history.

Amgen's 2002 acquisition of Immunex brought Enbrel under its portfolio, and the drug became Amgen's largest product through the 2000s and 2010s. Additional indications including psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis expanded its reach.

Patent litigation and exclusivity extended the US market longer than international markets, where biosimilars launched earlier. US biosimilar competition arrived later as exclusivity periods ran out, beginning the decline from peak sales.

About Amgen Inc.

What does Amgen own?
Amgen owns the Amgen brand and product brands including Enbrel, Prolia, Otezla, Neulasta, Repatha, Tezspire, and others. The Horizon acquisition added Tepezza, Krystexxa, and Uplizna.

Is Amgen publicly traded?
Yes. Amgen trades on Nasdaq under ticker AMGN and is a component of the S&P 500 and Dow Jones Industrial Average.

Who founded Amgen?
George Rathmann founded Applied Molecular Genetics in 1980 in Thousand Oaks, California. The name Amgen derives from the original.

Where is Amgen headquartered?
Amgen is headquartered in Thousand Oaks, California, USA.

Who owns Amgen?
Amgen is owned by public shareholders with no controlling investor. Robert Bradway serves as Chairman and CEO.

What is Amgen's revenue?
Amgen reported FY2025 total revenues of $36.8 billion, up 10%, with GAAP net income of $7.7 billion and non-GAAP EPS of $21.84.

What does Amgen make?
Amgen makes biologic medicines including Enbrel for rheumatoid arthritis, Prolia for osteoporosis, Otezla for psoriasis, and oncology and rare disease treatments.

Founded: 1980
Headquarters: Thousand Oaks, California, USA
Company Type: Publicly Traded
Stock: NASDAQ: AMGN
Revenue: $36.8 billion (FY2025)
Employees: Approximately 28,000

Visit Amgen Inc. website

View full company profile for Amgen Inc.

Where Is Enbrel Made / Based?

Headquarters: Thousand Oaks, California, USA (parent)
Manufacturing / Operations: United States, Ireland

Enbrel Categories & Tags

Pharmaceuticals Biologics Rheumatoid Arthritis Autoimmune Amgen

Enbrel Recalls & Controversies

As a biologic medication, Enbrel's issues are drug pricing, safety labeling, and patent litigation.

Drug pricing: Enbrel's US list price has been a prominent example in drug pricing debates, cited frequently in discussions of pharmaceutical affordability and international price comparisons.

Patent litigation: Amgen's extended exclusivity defense for Enbrel produced significant patent litigation, with questions about the thicket of patents that delayed US biosimilar entry longer than in Europe.

Safety labeling: TNF inhibitors carry boxed warnings about infection and malignancy risk, the class-wide labeling Enbrel shares with competitors.

Enbrel Ownership: Pros & Cons

Advantages

+One of the highest-selling drugs in pharmaceutical history
+Established safety profile from decades of use supports continued prescribing
+Amgen's biologics manufacturing expertise ensures supply reliability
+Still generates billions in annual sales even in decline phase
+Brand recognition among rheumatologists is unmatched

Considerations

-Sales declining from peak as newer agents and biosimilars take share
-Medicare price negotiation compresses US economics
-Patent exclusivity ended, exposing to biosimilar competition
-Newer mechanisms offer better efficacy for many patients
-IRA pricing trajectory will continue pressuring the brand

Frequently Asked Questions About Enbrel

Sources & Further Reading

Competitors to Enbrel

These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.

Brand	Parent Company	Country	Founded	Market Position	Primary Market	Gender Target
AmgenSister Brand	Amgen	USA	1980	Market leader	Global	All-ages
NeulastaSister Brand	Amgen	USA (parent)	2002	Market leader	Global	All-ages
ProliaSister Brand	Amgen	USA (parent)	2010	Market leader	Global	All-ages
Azasan	Bausch Health	Canada (Bausch Health Companies Inc.)	1968	Specialty	United states	Unisex
Xeljanz	Pfizer	USA	2012	Premium	Global	All Genders
OtezlaSister Brand	Amgen	USA (parent)	2014	Market leader	Global	All-ages